Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

If Safety Data Open Door In US, Cannabinoids’ Lawful Use In Supplements At Least A Year Off

Oct 09 2020

• By Eileen Francis

Marijuana Pot Weed Cannabis United States America USA Map 3d Illustration

Related Content

Lawful Use Of Cannabidiols In Supplements ‘Different Than The Rest’ Of US FDA Regulations?

Oct 07 2020

Unpublished And Under Review? US FDA’s CBD Policy Draft Guidance Still Has Industry Talking

Aug 04 2020

Drug Claims For CBD, Detoxification Supplements Make Warning List Along With Pandemic Fraud

Jun 11 2020

Waiting For Cannabidiol Guidance? US FDA Reminds Industry Of ‘Many Other Requirements’

Sep 23 2020

Temporary Funding For US Agencies Delays $5M For FDA’s Cannabidiols Regulatory Pathway Work

Sep 29 2020

US Bill For CBD Supplement Path Draws Mixed Industry Response

Sep 12 2020

House Appropriators Stoke Flames For FDA Regulation On CBD In Supplements

Mar 01 2019

Additional Topics

International United States US States Cannabidiol CBD Dietary Supplements FDA Advertising, Marketing & Sales Business Strategies Commercial Compliance Enforcement Guidance Documents Legislation Manufacturing Policy Regulation Consumer

More from Cannabis/CBD

More from Ingredients & Safety

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window